BidaskClub downgraded shares of Genomic Health (NASDAQ:GHDX) from a buy rating to a hold rating in a research report sent to investors on Tuesday, BidAskClub reports.

A number of other equities research analysts also recently issued reports on GHDX. Canaccord Genuity downgraded shares of Genomic Health from a buy rating to a hold rating and lowered their target price for the company from $77.00 to $72.00 in a report on Tuesday, July 30th. Barclays raised shares of Genomic Health from an underweight rating to an equal weight rating and lifted their price target for the company from $45.00 to $72.00 in a research report on Tuesday, July 30th. Zacks Investment Research raised shares of Genomic Health from a hold rating to a buy rating and set a $77.00 price target on the stock in a research report on Wednesday, July 31st. Deutsche Bank reduced their price target on shares of Genomic Health from $80.00 to $55.00 and set a hold rating on the stock in a research report on Thursday, May 30th. Finally, ValuEngine cut shares of Genomic Health from a buy rating to a hold rating in a research report on Tuesday, September 10th. Eleven analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $69.86.

Genomic Health stock opened at $70.80 on Tuesday. Genomic Health has a 1 year low of $50.77 and a 1 year high of $92.18. The firm has a 50 day moving average price of $73.59 and a 200 day moving average price of $64.93. The company has a market cap of $2.66 billion, a price-to-earnings ratio of 67.43 and a beta of 1.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.74 and a current ratio of 5.74.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.07. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The firm had revenue of $114.14 million during the quarter, compared to the consensus estimate of $110.78 million. During the same period in the previous year, the firm earned $0.23 earnings per share. Genomic Health’s revenue was up 19.4% compared to the same quarter last year. Sell-side analysts predict that Genomic Health will post 1.51 EPS for the current year.

In other news, insider James J. Vaughn sold 4,500 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $57.09, for a total transaction of $256,905.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kim Mceachron sold 5,335 shares of the business’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $60.01, for a total transaction of $320,153.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 394,238 shares of company stock worth $28,530,826. 31.30% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after purchasing an additional 493 shares in the last quarter. Manchester Capital Management LLC acquired a new position in shares of Genomic Health during the first quarter worth $56,000. Point72 Asset Management L.P. acquired a new position in shares of Genomic Health during the second quarter worth $93,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Genomic Health by 29.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock worth $112,000 after purchasing an additional 441 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Genomic Health by 12.7% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock worth $192,000 after purchasing an additional 372 shares in the last quarter. 94.00% of the stock is currently owned by institutional investors and hedge funds.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: Strangles

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.